In the 2011 review, EGCG was shown to become an androgen antagonist; when included to prostate cancer cells, EGCG physically interacted with the androgen receptor’s ligand-binding domain.This website features health, wellness, Exercise and nutritional info and it is made for educational reasons only. You shouldn't depend upon this details instead